Phase I Study of CDK 4-6 Inhibitor PD-0332991 (Palbociclib; IBRANCE) in Children With Recurrent, Progressive or Refractory Central Nervous System Tumors
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 35
- 试验地点
- 11
- 主要终点
- Single Dose Area Under the Plasma Concentration Time Curve (AUC)
研究概览
简要总结
This phase I trial studies the side effects and best dose of palbociclib isethionate in treating younger patients with central nervous system tumors that have grown, come back, or not responded to treatment. Palbociclib isethionate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
详细描述
PRIMARY OBJECTIVES:
I. To determine the maximum tolerated dose (MTD)/phase II recommended dose and describe toxicities related to PD-0332991 (palbociclib isethionate) in children with retinoblastoma protein 1 (Rb1) positive recurrent, progressive or refractory primary central nervous system (CNS) tumors.
II. To determine plasma pharmacokinetics of PD-0332991 in children with Rb1positive recurrent, progressive or refractory primary CNS tumors.
SECONDARY OBJECTIVES:
I. To record preliminary evidence of efficacy of PD-0332991 in children with recurrent CNS tumors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 4 Years 至 21 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with retinoblastoma protein (Rb1) positive recurrent, progressive or refractory central nervous system (CNS) tumors
- •Histologically confirmed Rb1 positive primary recurrent, progressive, or refractory central nervous system tumors; patients with low grade gliomas are excluded
- •Formalin fixed paraffin embedded tumor tissue (preferably from current recurrence) must be available to assess Rb1 protein status prior to enrollment; only patients with recurrent diffuse intrinsic brain stem glioma (DIPG) can be enrolled without the need for available tumor tissue for Rb1 protein status confirmation
- •Patients must have measurable disease (in 2-dimensions) on magnetic resonance imaging (MRI) scan of brain and/or spine to assess preliminary evidence of response
- •Body surface area (BSA):
- •Patients enrolled on dose level 1 (50 mg/m^2) must have BSA >= 1.20 m^2
- •Patients enrolled on dose level 2 (75 mg/m^2) must have BSA >= 0.93 m^2
- •Patients enrolled on dose level 3 (95 mg/m^2) must have BSA >= 0.70 m^2
- •Patients must have received no more than 2 prior chemotherapy regimens and/or focal radiotherapy for their brain tumor and fully recovered from the acute treatment related toxicities of all prior therapies prior to entering this study; for those acute baseline adverse events attributable to prior therapy, patients must meet organ function criteria
- •Chemotherapy: patients must have received their last dose of known myelosuppressive anticancer chemotherapy at least three (3) weeks prior to study enrollment in the study or at least six (6) weeks for those receiving nitrosourea
- •Biologic therapy: patients should have received their last dose of biologic agent >= 7 days prior to enrollment; in the event the patient has received another biologic agent and has experienced >= grade 2 myelosuppression, then at least three (3) weeks must have elapsed prior to enrollment; if the investigational or biologic agent has a prolonged half-life then at least three (3) weeks interval is required
- •Radiotherapy: patients must have had their last fraction of:
- •* Focal irradiation > 2 weeks prior to enrollment
- •Corticosteroids: patients who are receiving dexamethasone or other corticosteroids must be on a stable or decreasing dose for at least 1 week prior to enrollment; it is recommended that patients be off all steroid therapy or receive the least dose that will control their neurologic symptoms
- •Growth factors: all colony forming growth factor(s) have been discontinued for at least one week prior to enrollment (filgrastim, sargramostim, and erythropoietin); for patients on long acting growth factors, the interval should be two weeks
- •Patients with neurological deficits that are stable for a minimum of one week prior to registration
- •Patients must be able to swallow capsules
- •Karnofsky performance scale (KPS for > 16 years of age) or Lansky performance score (LPS for =< 16 years of age) assessed within two weeks of enrollment must be >= 60
- •Absolute neutrophil count >= 1,000/mm^3
- •Platelets >= 100,000/mm^3 transfusion independent (no platelet transfusion one week prior to enrollment)
- •Hemoglobin >= 8 g/dl
- •Total bilirubin =< 1.5 times upper limit of institutional normal (ULN) for age
- •Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x institutional upper limit of normal for age
- •Serum albumin >= 3 g/dL
- •Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 ml/min/1.73 m^2 or a serum creatinine based on age/gender as follows:
- •1 to < 2 years: 0.6 (male), 0.6 (female)
- •2 to < 6 years: 0.8 (male), 0.8 (female)
- •6 to < 10 years: 1 (male), 1 (female)
- •10 to < 13 years: 1.2 (male), 1.2 (female)
- •13 to < 16 years: 1.5 (male), 1.4 (female)
- •>= 16 years: 1.7 (male), 1.4 (female)
- •Female patients of childbearing potential must have a negative serum pregnancy test at the time of enrollment
- •Patients of childbearing or child fathering potential must be willing to use a medically acceptable form of birth control while being treated on this study
- •Patient and/or guardian have the ability to understand and the willingness to sign a written informed consent document according to institutional guidelines
排除标准
- •Patients with any clinical significant unrelated systemic illness (serious infections or significant cardiac, pulmonary, hepatic or other organ dysfunction) that is likely to interfere with the study procedures or results
- •Patients with low grade gliomas and Rb1 negative tumors
- •Patients who have received any of the following:
- •> 2 chemotherapy regimens
- •Myeloablative chemotherapy with stem cell rescue
- •Craniospinal irradiation
- •Patients with corrected QT (QTc) interval of > 450 msec or those on medications known to prolong QTc interval
- •Prior treatment on a CDK inhibitor
- •Patients who are receiving drugs that are strong inducers or inhibitors of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4)
- •Patients who are receiving any other investigational therapy
- •Patients who require enzyme inducing anti-convulsants to control seizures
- •Patients with cataracts on ophthalmologic examination
研究组 & 干预措施
Treatment (palbociclib isethionate)
Patients receive palbociclib isethionate PO QD on days 1-21. Treatment repeats every 4 weeks for 26 courses in the absence of disease progression or unacceptable toxicity.
干预措施: palbociclib isethionate (Drug)
Treatment (palbociclib isethionate)
Patients receive palbociclib isethionate PO QD on days 1-21. Treatment repeats every 4 weeks for 26 courses in the absence of disease progression or unacceptable toxicity.
干预措施: pharmacological study (Other)
Treatment (palbociclib isethionate)
Patients receive palbociclib isethionate PO QD on days 1-21. Treatment repeats every 4 weeks for 26 courses in the absence of disease progression or unacceptable toxicity.
干预措施: laboratory biomarker analysis (Other)
结局指标
主要结局
Single Dose Area Under the Plasma Concentration Time Curve (AUC)
时间窗: Up to day 3
On day 1 of course 1, series blood samples for palbociclib pharmacokinetic studies were collected at pre-dose, 0.5, 1, 2, 4, 8 (±1), 10 (±0.5) optional, 24 (±4), 48 (±4) hours after the oral dose of palbociclib. Area under the plasma concentration time curve (AUC) was estimated using a non-compartmental method.
Steady State Elimination Rate Constant (Ke)
时间窗: Up to day 22
On day 21 of course 1, series blood samples for palbociclib pharmacokinetic studies were collected at pre-dose, 1, 2, 4, 8 (±1), 10 (±0.5) optional, and 24 (±4) hours after the dose. Elimination rate constant (Ke) was estimated using a non-compartmental method.
Steady State Apparent Volume of Central Compartment (Vc/F)
时间窗: Up to day 22
On day 21 of course 1, series blood samples for palbociclib pharmacokinetic studies were collected at pre-dose, 1, 2, 4, 8 (±1), 10 (±0.5) optional, and 24 (±4) hours after the dose. Apparent volume of central compartment (Vc/F) was estimated using a non-compartmental method.
Steady State Half-life (t1/2)
时间窗: Up to day 22
On day 21 of course 1, series blood samples for palbociclib pharmacokinetic studies were collected at pre-dose, 1, 2, 4, 8 (±1), 10 (±0.5) optional, and 24 (±4) hours after the dose. Half-life (t1/2) was estimated using a non-compartmental method.
Maximum Tolerated Dose (MTD) of Palbociclib in Stratum I
时间窗: 4 weeks
Rolling-6 design was used to estimate MTD. The MTD was empirically defined as the highest dose level at which six patients were treated with at most one patient experiencing a dose-limiting toxicity (DLT) and the next higher dose level had been determined to be too toxic. Stratum I consisted of less-heavily pre-treated patients.
Maximum Tolerated Dose (MTD) of Palbociclib in Stratum II
时间窗: 4 weeks
Rolling-6 design was used to estimate MTD. The MTD was empirically defined as the highest dose level at which six patients were treated with at most one patient experiencing a DLT and the next higher dose level had been determined to be too toxic. Stratum II consisted of heavily pre-treated patients.
Number of Patients Who Experienced Dose Limiting Toxicities (DLTs)
时间窗: 4 weeks
DLTs were defined as any of the following adverse events that were at least possibly related to palbociclib that occurred during the first 4 weeks of therapy regardless of expectedness. Hematologic DLTs included grade 3 neutropenia with fever and sepsis, grade 3 thrombocytopenia and/or requiring a platelet transfusion on 2 separate days within a 7-day period, or any grade 4 hematologic toxicity except lymphopenia. Non-hematologic DLTs included any grade 4 non-hematologic toxicity, any grade 3 non-hematologic toxicity with some exceptions (e.g., nausea and vomiting of \< 5 days; diarrhea and/or electrolyte disturbances which have not been maximally treated; AST/ALT elevation that returns to levels meeting eligibility criteria within 7 days of study drug interruption and does not recur upon restarting drug), or any grade 2 non-hematologic toxicity that persists for \> 7 days and is considered medically significant or sufficiently intolerable by patients requires treatment interruption.
Single Dose Elimination Rate Constant (Ke)
时间窗: Up to day 3
On day 1 of course 1, series blood samples for palbociclib pharmacokinetic studies were collected at pre-dose, 0.5, 1, 2, 4, 8 (±1), 10 (±0.5) optional, 24 (±4), 48 (±4) hours after the oral dose of palbociclib. Elimination rate constant (Ke) was estimated using a non-compartmental method.
Single Dose Half-life (t1/2)
时间窗: Up to day 3
On day 1 of course 1, series blood samples for palbociclib pharmacokinetic studies were collected at pre-dose, 0.5, 1, 2, 4, 8 (±1), 10 (±0.5) optional, 24 (±4), 48 (±4) hours after the oral dose of palbociclib. Half-life (t1/2) was estimated using a non-compartmental method.
Single Dose Apparent Oral Clearance (CL/F)
时间窗: Up to day 3
On day 1 of course 1, series blood samples for palbociclib pharmacokinetic studies were collected at pre-dose, 0.5, 1, 2, 4, 8 (±1), 10 (±0.5) optional, 24 (±4), 48 (±4) hours after the oral dose of palbociclib. Apparent oral clearance (CL/F) was estimated using a non-compartmental method.
Steady State Apparent Oral Clearance (CL/F)
时间窗: Up to day 22
On day 21 of course 1, series blood samples for palbociclib pharmacokinetic studies were collected at pre-dose, 1, 2, 4, 8 (±1), 10 (±0.5) optional, and 24 (±4) hours after the dose. Apparent oral clearance (CL/F) was estimated using a non-compartmental method.
Steady State Area Under the Plasma Concentration Time Curve (AUC)
时间窗: Up to day 22
On day 21 of course 1, series blood samples for palbociclib pharmacokinetic studies were collected at pre-dose, 1, 2, 4, 8 (±1), 10 (±0.5) optional, and 24 (±4) hours after the dose. Area under the plasma concentration time curve (AUC) was estimated using a non-compartmental method.
Single Dose Apparent Volume of Central Compartment (Vc/F)
时间窗: Up to day 3
On day 1 of course 1, series blood samples for palbociclib pharmacokinetic studies were collected at pre-dose, 0.5, 1, 2, 4, 8 (±1), 10 (±0.5) optional, 24 (±4), 48 (±4) hours after the oral dose of palbociclib. Apparent volume of central compartment (Vc/F) was estimated using a non-compartmental method.
次要结局
- Number of Subjects With Objective Responses(Up to 2 years)
- Association Between Leukopenia and Single Dose Palbociclib AUC(Up to approximately 4 weeks)
- Association Between Neutropenia and Single Dose Palbociclib AUC(Up to approximately 4 weeks)
- Association Between Lymphopenia and Single Dose Palbociclib AUC(Up to approximately 4 weeks)